Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells

The clinical success of EGFR inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Here, we show that inhibition of SREBP increase gefitinib sensitivity in vitro and in vivo. Interference of SREBP1 binding partner MARVELD1 potentiate the therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiajin, Yan, Hui, Zhao, Li, Jia, Wenzhi, Yang, Hao, Liu, Liu, Zhou, Xiang, Miao, Ping, Sun, Xiaoguang, Song, Shaoli, Zhao, Xiaoping, Liu, Jianjun, Huang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239560/
https://www.ncbi.nlm.nih.gov/pubmed/27447558
http://dx.doi.org/10.18632/oncotarget.10721
Descripción
Sumario:The clinical success of EGFR inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Here, we show that inhibition of SREBP increase gefitinib sensitivity in vitro and in vivo. Interference of SREBP1 binding partner MARVELD1 potentiate the therapeutic effect of gefitinib as well. Mechanistically, SREBP inhibition decreases the cell membrane fluidity, results in a decreased tyrosine phosphorylation of EGFR. Therefore, targeting lipid metabolism combined with EGFR-TKIs is potentially a novel therapeutic strategies for cancer treatment.

Ejemplares similares